Daiwa Securities Group
JAZZ icon

Daiwa Securities Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Daiwa Securities Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-600
Closed -$273K – 1306
2024
Q2 		$273K Buy
+600
New +$66K ﹤0.01% 931

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Daiwa Securities Group's JAZZ Position: Q1 2026 in Review

Daiwa Securities Group increased its Jazz Pharmaceuticals (JAZZ) stake by 75% in Q1 2026, buying an estimated $1.12M and bringing the position to 15,000 shares worth $2.84M. The position accounts for 0.01% of the portfolio, ranked #597.

Daiwa Securities Group first reported a position in JAZZ in Q4 2014 and has held it in 46 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Daiwa Securities Group held 15,000 shares of Jazz Pharmaceuticals worth $2.84M as of Q1 2026.
  • Daiwa Securities Group bought 6,417 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.12M.
  • Jazz Pharmaceuticals made up 0.01% of Daiwa Securities Group's portfolio in Q1 2026, its #597 holding.
  • Daiwa Securities Group first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.